9 Analysts Have This to Say About Harmony Biosciences
Portfolio Pulse from Benzinga Insights
Harmony Biosciences (NASDAQ:HRMY) has received 9 analyst ratings in the last quarter, with 6 being bullish, 3 somewhat bullish, and none being bearish or indifferent. The average 12-month price target for the company is $63.67, a decrease of 3.05% from the previous average of $65.67.
September 07, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences has received positive analyst ratings, which could boost investor confidence and potentially increase the stock price.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings for Harmony Biosciences indicate a positive outlook for the company, which could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100